From R&D to Commercial Manufacturing: Scale-Up in Single-Use Bioreactors

Finnish Herantis Pharma has extended the placebo-controlled period of its upcoming Phase II study of HER-096 in Parkinson’s disease. The company points to newly published evidence that smartphone-based motor assessments detect disease progression more sensitively than conventional clinical measures.

Sarah Fredriksson, former CEO of Aqilion and founder of Genovis, took over as CEO of AAX Biotech on November 1, 2026. Co-founder Daniel X Johansson remains Chief Scientific Officer (CSO) and board member.

US-based ANI Pharmaceuticals has made a public cash offer for Egetis Therapeutics worth about SEK 5.3 billion. The Egetis board unanimously recommends that shareholders accept.

Boule Diagnostics will stop developing, manufacturing and selling hematology instruments, and will focus instead on consumables, service and its US contract manufacturing business. To fund the transition, the company plans a fully secured rights issue of about SEK 93 million.

Novo has raised its full-year 2026 outlook after a stronger-than-expected third quarter. Adjusted sales and adjusted operating profit are now both expected to change by −2% to +2% at constant exchange rates, up from 0% to −6% previously, driven by higher expectations for GLP-1 sales. It is the company’s third outlook upgrade this year.

Egetis Therapeutics has agreed to sell its US Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD 190 million, about SEK 1.9 billion. About half of the net proceeds will go to the former owners of Rare Thyroid Therapeutics International (RTTI).

Finnish Nightingale Health has signed two proteomics service agreements worth USD 1 million each, one with Alzheimer’s Research UK and one with medical research organization LifeArc. Both cover analysis of UK Biobank samples for research into neurodegenerative diseases.